Universal Quantum Announced a Series A of More Than $100 Million on 8 October 2026: What Published Cytochrome P450 Resource Estimates Say About Quantum Drug-Metabolism Chemistry
Universal Quantum funds trapped-ion machines with drug discovery in view
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 8 October 2026 the University of Sussex announced that its spin-out Universal Quantum had raised a Series A round of more than $100 million, co-led by Firgun Ventures and DCVC. The university calls it the largest Series A raised by a UK quantum company and the company's first significant institutional financing. Universal Quantum builds trapped-ion quantum computers from linked chip modules, and it lists drug discovery among the uses that larger, error-corrected machines could open up.
For readers in hospitals and pharmaceutical research, the useful question behind the money is how large a machine has to become before it can calculate something a medicinal chemist cannot already calculate on a classical computer. One published benchmark concerns the cytochrome P450 enzymes, which break down most medicines in the liver, and its estimate runs to millions of physical qubits on a generic error-corrected machine.
The university's announcement names further investors, among them the Singapore investor EDBI, Invus, Integral GlobalTech, Main Sequence, Hostplus, NGS Super and Roblox founder Dave Baszucki. Chief executive Sebastian Weidt, who co-founded the company with physicist Winfried Hensinger, said the round reflects investors' belief that Universal Quantum offers "one of the most credible paths to quantum computing at scale." The university states that the company now employs more than 100 people on three continents.
A trapped-ion computer holds single charged atoms in electric fields above a chip and uses each ion as a qubit. Most trapped-ion systems address their ions with many finely aimed laser beams. Universal Quantum follows the design that Hensinger and Weidt published in 2017 as a blueprint for a large machine, in which a global microwave field drives the qubit operations and local voltages select which ions respond. According to reporting by Tech.eu on the round, the company's chip carries hundreds of ion qubits on a die larger than 400 square millimeters and is made on a standard 200-millimeter commercial foundry line.
The harder engineering problem is connecting chips. In a paper in Nature Communications of 8 February 2023, Mamun Akhtar and colleagues in Hensinger's Sussex group moved ions physically from one chip module to the next at a rate of 2,424 transfers per second, with a probability below 7 in 100 million that an ion is lost during a transfer. Separately, the authors found no measurable loss of the qubits' phase coherence from the transport. That link is the basis of the modular, tileable machine the company wants to build. Tech.eu also reports a €67 million contract from the German Aerospace Center (DLR) in 2023 and a hub in Hamburg that the new money will expand, alongside growth in the United States and Japan.
Drug safety depends heavily on metabolism. A Google Research post by Nicholas Rubin and Ryan Babbush of 12 October 2023 notes that enzymes of the P450 family carry out more than 70 percent of all drug metabolism. When two drugs compete for the same P450 enzyme, levels of one can rise into a toxic range; when a patient's genes make an enzyme fast or slow, a standard dose can be too weak or too strong. Predicting how a new molecule binds and reacts at the iron center of these enzymes is therefore a real problem in pharmaceutical development.